The fight against sexually transmitted infections (STIs) is gaining momentum, fueled by advancements in diagnostic testing. The global CTNG Testing Market, encompassing tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), is on a surge. Valued at USD 1.8 billion in 2023, this market is projected to reach a staggering USD 3.9 billion by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 8.0%.
The CTNG testing industry is expected to grow considerably due to increasing awareness of sexual health. The prevalence of CT and NG infections is rising, driving research and technological advancements for efficient, precise, and easily accessible testing methods. Telemedicine and at-home testing kits are transforming the industry and improving public health outcomes.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-18144
The cost of laboratory diagnostics is significantly influenced by variable costs associated with reagents and instruments, as well as supplier fees. Additional expenses, such as maintenance and insurance, laboratory supervision, and administrative costs, add to the overall cost. Only major hospitals and reference labs with substantial capital budgets can bear the enormous cost of diagnostic equipment. Conversely, small laboratories, physicians’ offices, and individual practitioners often require more capital, making it difficult for them to purchase costly instruments and analyzers.
Efficient collection, storage, and transportation of samples are crucial in clinical laboratories. Nevertheless, technicians need help in achieving this. Redesigning laboratory areas to conduct specific diagnostic procedures for pathogen detection is necessary to ensure time management and prevent cross-contamination. As a result, the maintenance and operation costs of modern CTNG devices, especially those designed to handle a single type of sample, have significantly increased.
In addition, to keep up with the fast mutation of micro-organisms and the increasing number of epidemic outbreaks, clinical testing facilities are adopting advanced diagnostic technologies that provide rapid sample diagnosis. Nevertheless, the widespread utilization of modern molecular diagnostic technologies faces obstacles, especially in developing nations, as there is a need for more experienced and technically skilled laboratory employees. Nevertheless, the development of the CTNG testing market is restrained by operational obstacles and the high cost of CTNG testing equipment.
“The growth of the CTNG market is being driven by various factors, including the rising incidence rate of CTNG infections, growing investments and funding, and increased awareness of disease diagnosis. Launching novel products and acquiring commercial enterprises are some of the most widely adopted strategies by the market players,” opines Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI).
CTNG Testing Market Key Takeaways:
- The global CTNG testing market is projected to register a CAGR of 8.0% with a valuation of US$ 3.9 billion by 2033.
- The market captured a CAGR of 10.2% in the historical period from 2018 and 2022.
- South Korea is anticipated to dominate the global market by registering a 13.8% CAGR during the forecast period.
- With a CAGR of 12.7%, Japan is expected to drive the global market through 2033.
- The United Kingdom is anticipated to secure a CAGR of 12.2% during the forecast period.
Competition Analysis:
Many companies in the CTNG testing market have capitalized on the significant growth opportunities in emerging economies. The investments made in healthcare and life science research in these markets have resulted in improvements in laboratory infrastructure. This development has aided in the installation of diagnostic systems in laboratories, ultimately leading to the increasing adoption of CTNG testing.
Buy Report Now:
https://www.futuremarketinsights.com/checkout/18144
Recent Developments:
- Hologic, Inc. launched its latest Aptima CT/NG Assay in March 2023. This advanced molecular diagnostic test can efficiently detect CT and NG DNA in a single sample. It is highly sensitive and can generate results in just under two hours.
- BD, also known as Becton, Dickinson, and Company, introduced its new BD SurePath LCT/NG Test in February 2023. The test can detect CT and NG DNA in a single sample through nucleic acid amplification. Additionally, the test is remarkably accurate and can produce results in under two hours.
- In January 2023, Quest Diagnostics launched the Aptima CT/NG Assay in its clinical laboratories. The patients can get tested for CT and NG at Quest Diagnostics locations across the United States.
CTNG Testing Market Key Companies:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Hologic, Inc. (USA)
- Thermo Fisher Scientific Inc. (USA)
- Abbott Laboratories (USA)
- Bio-Rad Laboratories, Inc. (USA)
- Siemens Healthineers AG (Germany)
- Becton, Dickinson, and Co. (BD)
- Linear Diagnostics
- TIB Molbiol (Germany)
- Quest Diagnostics
CTNG Testing Market Segmentation
By Product:
- Assays & kits
- Instruments/Analyzers
By Test Type:
- Laboratory
- Point-of-care Testing
By Technology:
- INAAT
- PCR
- Immunodiagnostics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
